Author's response to reviews

Title: Snake venom toxin from Vipera lebetina turanica induces apoptosis in colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression

Authors:

Mi Hee Park (pmh5205@hanmail.net)
Mi Ran Jo (jmryvksh@naver.com)
Dohee Won (wdh7379@hotmail.com)
Ho Sueb Song (hssong70@kyungwon.ac.kr)
Sang Bae Han (shan@chungbuk.ac.kr)
Min Jong Song (bitsugar@hanmail.net)
Jin Tae Hong (jinthong@chungbuk.ac.kr)

Version: 4 Date: 7 May 2012

Author's response to reviews: see over
Dear Editor-in-Chief, Journal (BMC Cancer)

May 7, 2012

Thanks for your letter regarding our manuscript (MS# 1150374584670284) “Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression” together with the thoughtful comments from the reviewer. We have carefully considered the reviewer’s comments and have edited our manuscript accordingly.

LIST OF CORRECTIONS ON THE MANUSCRIPT

Steven de Jong REVIEWER’S COMMENTS

The response to the reviewer’s comment:
We authors express our thanks to the Steven de Jong reviewer who have given useful advices on this manuscript.

Reviewer's comment
The authors have improved the manuscript and added new results to the manuscript and improved blots. The authors did not add cell surface expression levels of DR4 and DR5. In stead, they refer to two previous articles where HCT116 was used (not HT29) but with different drugs. To what extent those results can be extrapolated to venom effects I don't know. Since the article is partially focussing on DR4/5 expression and down regulation, I think flow cytometry would have been better.

Author’s response
Thank you for your comment. We checked the cell surface expression of DR4 and DR5 by flow cytometry analysis in HCT116 cell. We showed that the cell surface expression of DR4 and DR5 was increased accompanied with western blot data. But,
we couldn’t check that in HT-29 cells. So we didn’t insert the flow cytometry data in revised MS, but the western blot data may be sufficient.

**Reviewer's comment**
The authors state that LY303511 is a phosphoinositide 3-kinase (PI3K) inhibitor. However, this drug works in a PI3K independent way.

**Author’s response**
Thank you for your comment. We deleted the “a phosphoinositide 3-kinase (PI3K) inhibitor” in 2nd revised MS.

**Reviewer's comment**
Abstract: Abundent = Abundant
Background 2nd page activition= activation

**Author’s response**
Thank you for your comment. We corrected the words in 2nd revised MS.
Reviewer's comment
Ref 7, wrong spellings Duikera, Moma, de JS= Duiker, Mom, de Jong
Ref 36 and 37 (and possible others as well) are lacking authors after the third author.
Otherwise they should add: et al.

Author's response
Thank you for your comment. In Ref 7, we corrected the wrong spellings of authors.
In Ref 36 and 37, we inserted the lacking authors and changed to Ref 34 and 35 in
2nd revised MS because we deleted the Ref.32 and 33.

This revised manuscript consists of 35 pages of text with 6 Figures and 1
Supplementary Figure.

We hope that this revised manuscript would be accepted for publication in the
“BMC Cancer”.

Sincerely,
Jin Tae Hong, Ph.D
College of Pharmacy
Chungbuk National University
12, Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Korea
Tel: 82-043-261-2813, Fax: 82-043-268-2732
E-mail:jinthong@chungbuk.ac.kr